


~~We~~  
claim:


1. A method of avoiding hyperphosphatemia while treating a patient having a kidney disorder comprising administering to said patient a vitamin D compound that has a minimal effect on serum phosphorus of said patient.
2. The method of claim 1 wherein said kidney disorder is uremia.
3. The method of claim 1 wherein said kidney disorder is renal failure.
4. The method of claim 1 wherein said vitamin D compound is administered together with a pharmaceutically acceptable excipient.
5. The method of claim 1 wherein said vitamin D compound is in a solid or liquid vehicle ingestible by and non-toxic to the patient.
6. The method of claim 1 wherein said vitamin D compound is a 19-nor-vitamin D compound.
7. The method of claim 6 wherein said 19-nor-vitamin D compound has the formula:



where  $X^1$  and  $X^2$  each represent, independently, hydrogen or a hydroxy-protecting group, and where R is represented by the structure below:



where the stereochemical center may have the R or S configuration, and where Z is selected from Y, -OY, -CH<sub>2</sub>OY, -C ≡ CY and -CH = CHY, where the double bond may have the cis or trans geometry, and where Y is selected from hydrogen, methyl, -CR<sup>5</sup>O and a radical of the structure.



where m and n, independently, represent integers from 0 to 5, where R<sup>1</sup> is selected from hydrogen, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C<sub>1-5</sub> alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent, and where each of R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup>, independently, is selected from hydrogen, fluoro, trifluoromethyl and C<sub>1-5</sub> alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent, and where R<sup>1</sup> and R<sup>2</sup>, taken together represent an oxo group, or an alkylidene group, =CR<sup>2</sup>R<sup>3</sup>, or the group -(CH<sub>2</sub>)<sub>p</sub>-, where p is an integer from 2 to 5, and where R<sup>3</sup> and R<sup>4</sup>, taken together, represent an oxo group, or a group -(CH<sub>2</sub>)<sub>q</sub>-, where q is an integer from 2 to 5, where R<sup>5</sup> represents hydrogen, hydroxy, protected hydroxy, or C<sub>1-5</sub> alkyl, and where any of the groups at positions 20, 22 and 23, respectively in the side chain may be replaced by an oxygen atom.

8. The method of claim 1 where the said vitamin D compound is  $1\alpha,25$ -dihydroxy-19-nor-vitamin D<sub>3</sub>.

9. The method of claim 1 where the said vitamin D compound is  $1\alpha$ -hydroxy-19-nor-vitamin D<sub>3</sub>.

10. The method of claim 1 where the said vitamin D compound is  $1\alpha,25$ -dihydroxy-19-nor-vitamin D<sub>2</sub>.

11. The method of claim 1 where the said vitamin D compound is  $1\alpha$ -hydroxy-19-nor-vitamin D<sub>2</sub>.

12. The method of claim 1 where the said vitamin D compound is  $1\alpha$ -hydroxy-19-nor-24-epi-vitamin D<sub>2</sub>.

13. The method of claim 1 where the said vitamin D compound is  $1\alpha,25$ -dihydroxy-19-nor-24-epi-vitamin D<sub>2</sub>.

14. The method of claim 1 where the said vitamin D compound is administered orally.

15. The method of claim 1 where the said vitamin D compound is administered parenterally.

16. The method of claim 1 where the said vitamin D compound is administered topically.

17. The method of claim 1 where the said vitamin D compound is administered in an amount from 1  $\mu$ g to about 500  $\mu$ g per day to the patient.

Add.  
a27